MedTrace Logo

Study of EB-001 in Facial Scar Reduction

NCT03346902 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.

Conditions

  • Mohs Surgery

Interventions

DRUG

EB-001

Injection of EB-001 into area of scarring (forehead)

DRUG

0.9% Sodium Chloride Injection

Injection of Saline into area of scarring (forehead)

Sponsors & Collaborators

  • Bonti, Inc.

    lead INDUSTRY

Principal Investigators

  • Earvin Liang · Bonti, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-06
Primary Completion
2018-07-31
Completion
2018-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03346902 on ClinicalTrials.gov